参考文献/References:
[1] KIDDEE W,TROPE G E,SHENG L A,SMITH M,STRUNGARU M,BUYS Y M.Intraocular pressure monitoring post intravitreal steroids:a systematic review[J].Surv Ophthalmol,2013,58(4):291-310.
[2] CAMPOCHIARO P A,BROWN D M,PEARSON A,CHEN S,BOYER D,RUIZ-MORENO J,et al.Sustained delivery fluoci-nolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema[J].Ophthalmology,2012,119(10):2125-2132.
[3] AUGUSTIN A J,BOPP S,FECHNER M,HOLZ F,SANDNER D,WINKGEN A M,et al.Three-year results from the Retro-IDEAL study:real-world data from diabetic macular edema(DME)patients treated with ILUVIEN?(0.19 mg fluocinolone acetonide implant)[J].Eur J Ophthalmol,2020,30(2):382-391.
[4] BOYER D S,YOON Y H,BELFORT R,BANDELLO F,MATURI R K,AUGUSTIN A J,et al.Three-year,randomized,sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema[J].Ophthalmology,2014,121(10):1904-1914.
[5] ARRIGO A,ARAGONA E,CAPONE L,DI BIASE C,LATTANZIO R,BANDELLO F.Intraocular pressure changes are predictive of ocular hypertension onset after fluocinolone acetonide implant:significant cutoffs and the role of previous DEX implant[J].Front Med (Lausanne),2021,8:725349.
[6] GOI F J,STALMANS I,DENIS P,NORDMANN J P,TAYLOR S,DIESTELHORST M,et al.Elevated intraocular pressure after intravitreal steroid injection in diabetic macular edema:monitoring and management[J].Ophthalmol Ther,2016,5(1):47-61.
[7] ZARRANZ-VENTURA J,SALA-PUIGDOLLERS A,VELAZQUEZ-VILLORIA D,FIGUERAS-ROCA M,COPETE S,DISTEFANO L,et al.Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world[J].PLoS One,2019,14(1):e0209997.
[8] ZUR D,IGLICKI M,LOEWENSTEIN A.The role of steroids in the management of diabetic macular edema[J].Ophthalmic Res,2019,62(4):231-236.
[9] FALLICO M,MAUGERI A,LOTERY A,LONGO A,BONFIGLIO V,RUSSO A,et al.Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema:a systematic review with meta-analysis of real-world experience[J].Sci Rep,2021,11(1):4800.
[10] GOI F J,BARTON K,DIAS J A,DIESTELHORST M,GARCIA-FEIJOO J,HOMMER A,et al.Intravitreal corticosteroid implantation in diabetic macular edema:updated European consensus guidance on monitoring and managing intraocular pressure[J].Ophthalmol Ther,2022,11(1):15-34.
[11] YEMANYI F,YEMANYI F,BAIDOURI H,BURNS A R,RAGHUNATHAN V.Dexamethasone and glucocorticoid-induced matrix temporally modulate key integrins,caveolins,contractility,and stiffness in human trabecular meshwork cells[J].Invest Ophthalmol Vis Sci,2020,61(13):16.
[12] KUBOTA T,OKABE H,HISATOMI T,YAMAKIRI K,SAKAMOTO T,TAWARA A.Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide[J].J Glaucoma,2006,15(2):117-119.
[13] JOHNSON D,GOTTANKA J,FLGEL C,HOFFMANN F,FUTA R,LTJEN-DRECOLL E.Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids[J].Arch Ophthalmol,1997,115(3):375-383.
[14] STEELY H T,BROWDER S L,JULIAN M B,MIGGANS S T,WILSON K L,CLARK A F.The effects of dexamethasone on fibronectin expression in cultured human trabecular meshwork cells[J].Invest Ophthalmol Vis Sci,1992,33(7):2242-2250.
[15] ROHEN J W,LINNR E,WITMER R.Electron microscopic studies on the trabecular meshwork in two cases of corticosteroid-glaucoma[J].Exp Eye Res,1973,17(1):19-31.
[16] PHULKE S,KAUSHIK S,KAUR S,PANDAV S S.Steroid-induced glaucoma:an avoidable irreversible blindness[J].J Curr Glaucoma Pract,2017,11(2):67-72.
[17] VI A L,KODJIKIAN L,MALCLS A,AGARD E,VOIRIN N,EL C H,et al.Tolerance of intravitreal dexamethasone implants in patients with ocular hypertension or open-angle glaucoma[J].Retina,2017,37(1):173-178.
[18] MAZZARELLA S,MATEO C,FREIXES S,BURES J A,RIOS J,NAVARRO R,et al.Effect of intravitreal injection of dexamethasone 0.7 mg(Ozurdex?)on intraocular pressure in patients with macular edema[J].Ophthalmic Res,2015,54(3):143-149.
[19] VASCONCELOS-SANTOS D V,NEHEMY P G,SCHACHAT A P,NEHEMY M B.Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide:incidence and risk factors[J].Retina,2008,28(4):573-580.
[20] ARMALY M F.Effect of corticosteroids on intraocular pressure and fluid dynamics.II.The effect of dexamethasone in the glaucomatous eye[J].Arch Ophthalmol,1963,70:492-499.
[21] ARMALY M F.Effect of corticosteroids on intraocular pressure and fluid dynamics.I.The effect of dexamethasone in the normal eye[J].Arch Ophthalmol,1963,70:482-491.
[22] MALCLS A,DOT C,VOIRIN N,VI A L,AGARD ,BELLOCQ D,et al.Safety of intravitreal dexamethasone implant (OZURDEX):the SAFODEX study.Incidence and risk factors of ocular hypertension[J].Retina,2017,37(7):1352-1359.
[23] CHAKRAVARTHY U,TAYLOR S R,KOCH F J.CASTRO D E,SOUSA J P,BAILEY C,et al.Changes in intraocular pressure after intravitreal fluocinolone acetonide(ILUVIEN):real-world experience in three European countries[J].Br J Ophthalmol,2019,103(8):1072-1077.
[24] DE MORAES C G,LIEBMANN J M,LEVIN L A.Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma[J].Prog Retin Eye Res,2017,56:107-147.
[25] ROBERTI G,ODDONE F,AGNIFILI L,KATSANOS A,MICHELESSI M,MASTROPASQUA L,et al.Steroid-induced glaucoma:epidemiology,pathophysiology,and clinical management[J].Surv Ophthalmol,2020,65(4):458-472.
[26] KERSEY J P,BROADWAY D C.Corticosteroid-induced glaucoma:a review of the literature[J].Eye (Lond),2006,20(4):407-416.
[27] RAZEGHINEJAD M R,KATZ L J.Steroid-induced iatrogenic glaucoma[J].Ophthalmic Res,2012,47(2):66-80.
[28] CHOI M Y,KWON J W.Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema[J].Sci Rep,2020,10(1):13736.
[29] BAILEY C,CHAKRAVARTHY U,LOTERY A,MENON G,TALKS J,MEDISOFT AUDIT G.Extended real-world experience with the ILUVIEN? (fluocinolone acetonide) implant in the United Kingdom:3-year results from the Medisoft? audit study[J].Eye (Lond),2022,36(5):1012-1018.
[30] HEMARAT K,KEMMER J D,PORCO T C,EATON A M,KHURANA R N,STEWART J M.Secondary ocular hypertension and the risk of glaucoma surgery after dexamethasone intravitreal implant in routine clinical practice[J].Ophthalmic Surg Lasers Imaging Retina,2018,49(9):680-685.
[31] 沈燕燕,邵毅,吴晓蓉,梅锋.缓释激素植入物治疗黄斑水肿的研究进展[J].眼科新进展,2019,39(9):891-896.
SHEN Y Y,SHAO Y,WU X R,MEI F.Slow-release hormone implants in the treatment of macular edema[J].Rec Adv Ophthalmol,2019,39(9):891-896.
[32] CHOI W,PARK S E,KANG H G,BYEON S H,KIM S S,KOH H J,et al.Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients[J].Br J Ophthalmol,2019,103(10):1380-1387.